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Ixodes ricinus transmits bacterial, protozoal and viral pathogens, causing disease and forming an increasing health
concern in Europe. ANTIDotE is an European Commission funded consortium of seven institutes, which aims to
identify and characterize tick proteins involved in feeding and pathogen transmission. The knowledge gained will
be used to develop and evaluate anti-tick vaccines that may prevent multiple human tick-borne diseases. Strategies
encompassing anti-tick vaccines to prevent transmission of pathogens to humans, animals or wildlife will be
developed with relevant stakeholders with the ultimate aim of reducing the incidence of tick-borne diseases in
humans.
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Tick-borne diseases as a public health concern in Europe
Ixodes ricinus is a hard tick that transmits a variety of
pathogens of medical and veterinary importance. These
include Borrelia burgdorferi sensu lato, Borrelia miyamo-
toi, Anaplasma phagocytophilum, Rickettsia spp., Babe-
sia spp., and tick-borne encephalitis virus (TBEV). The
most prevalent tick-borne infection of humans in Europe
is Lyme borreliosis, with at least 65,000 documented
cases yearly [1]. The most pathogenic infection is caused
by TBEV, with 1 to 2% of patients reportedly dying from
the European subtype [2], and with up to 46% of TBE
patients suffering from long-term sequelae [3]. Infection
of most other tick-borne pathogens associated with I.
ricinus, such as Babesia spp., but also B. miyamotoi, is
usually mild and may easily go undiagnosed. However,
infection of immunocompromised individuals can lead
to a progressive and more severe illness [4,5]. A rela-
tively low number of severe human babesiosis cases have* Correspondence: hein.sprong@rivm.nl; j.w.hovius@amc.uva.nl
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unless otherwise stated.been reported in literature, which is surprising considering
the widespread distribution of Babesia-infected ticks and
the size of the population at risk [6].
The incidences of Lyme borreliosis and tick-borne en-
cephalitis are on the rise in several European countries
[1,2,7] and diseases caused by other pathogens, such as
Neoehrlichia mikurensis, and B. miyamotoi are clearly
emerging [5,8]. Environmental (e.g. climate change and
landscape management), socio-economic and demo-
graphic factors (e.g. population aging and life-styles)
synergistically increase the risk of acquiring tick-borne
diseases [9-13]. Based on these findings, the European
Center for Disease Prevention and Control has pre-
dicted that the incidence of tick-borne diseases will
rise in the near future [14]. Therefore, the old adage
‘prevention is better than cure’ also holds true for tick-
borne diseases.Current control measures
Conventional control measures on tick-borne zoonoses,
such as the widespread application of detrimental acari-
cides to control ticks and the culling of wildlife reservoirs,
are becoming more and more socially unacceptable [15].
Where the risk of infection is high, and/or the resulting
disease severe, vaccines may be the most efficient and cost-
effective means of prevention and control [16]. Anti-tickLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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being used in the veterinary field. The strategy behind
these vaccines is to locally control Rhipicephalus (Boophi-
lus) tick species, and act as a safe and environmentally
friendly alternative to acaricides [17,18]. Application of
anti-tick vaccines was shown to dramatically decrease the
incidence of bovine babesiosis [19]. Whether anti-tick vac-
cines can also be used to (locally) eradicate I. ricinus, and
prevent human tick-borne diseases remains to be estab-
lished. It may not prove to be a easy challenge due to the
very large host range of I. ricinus and its ability to survive
in a variety of habitats, including deciduous and coniferous
woodlands, heathlands, moorlands, rough pastures, forests,
urban parks, and even gardens [20].
Vaccines against TBEV are available, but require mul-
tiple doses and frequent boosters to induce and maintain
immunity [21] and the vaccination coverage in many
Central and Eastern Europe is remarkably low [22]. A
vaccine protecting against Lyme borreliosis is unavail-
able, but a refined vaccine has recently been tested in a
Phase I/II trial [23]. Based on the experiences with the
previous Lyme vaccine that was on the American market
from 1998 to 2002, it remains to be seen whether a
Lyme vaccine will be widely used [24]. There is no hu-
man vaccine to prevent babesiosis or any other of the
other above-mentioned pathogens. Ideally, one would
like to have a single vaccine (for humans), protecting
against multiple tick-borne diseases.Figure 1 The participants of the official launch meeting of ANTIDotE.
December 2013.The idea behind ANTIDotE
Rather than developing vaccines against all the patho-
gens transmitted by I. ricinus, one vaccine targeting the
tick itself could have the same effect by blocking the
transmission of any pathogen. The idea of such a vac-
cine is supported by the observation that multiple expo-
sures of certain mammalian species to tick bites results
in an inability of ticks to successfully take a blood meal,
a phenomenon designated as ‘tick immunity’ [25,26].
Ixodes ticks not only introduce pathogens, but also saliv-
ary proteins into the host skin that facilitate their feeding
and even the transmission of pathogens by modulating
host defense mechanisms. Anti-tick immune responses
are based on both cellular and humoral immune re-
sponses directed against selected tick (salivary gland) anti-
gens. Of paramount importance, ‘tick immunity’ impairs
tick feeding, but also protects animals from the develop-
ment of experimental infections with tick-borne patho-
gens [27-29]. These anti-tick immune responses can be
simulated by vaccination of laboratory animals with tick
salivary gland extract or selected tick salivary gland pro-
teins [30]. In addition, targeting tick salivary proteins that
facilitate the transmission of pathogens from the tick to
the host by (neutralizing) antibodies may also prevent suc-
cessful pathogen transmission, without affecting the tick’s
ability to feed [31-33]. Notably, humans with hypersensi-
tivity to tick-bites are also at a lower risk of contracting
Lyme borreliosis [34]. In other words, the identificationThis meeting was held in Amsterdam, The Netherlands, in
Figure 2 (See legend on next page.)
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Figure 2 The ANTIDotE approach. Identification: Using state of the art proteomic and transcriptomic approaches we will identify novel tick
salivary gland proteins. Characterization: These novel tick salivary gland proteins will be characterized using in silico, in vitro and in vivo techniques.
Proof of concept: Promising candidates will be assessed in a proof of concept study as anti-tick vaccines to protect against tick-borne diseases.
Both transmission as well as tick feeding parameters will be assessed. The symbols (from left to right) represent Babesia, Borrelia nd TBEV, respectively.
Valorization plans: Through an integrated and multidisciplinary approach involving European public health institutes, health organizations and industrial
companies, we will examine how to develop anti-tick vaccines and implement these in public health systems in Europe.
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volved in feeding and transmission of bacteria, viruses and
protozoa will greatly facilitate the development of an anti-
tick vaccine that could prevent multiple human tick-borne
diseases. Such a vaccine could either be used in humans
directly, or in animals and wildlife in order to indirectly
reduce the risk of contracting tick-borne disease for
humans.
The ANTIDotE consortium and project
The ANTIDotE consortium
ANTIDotE is the acronym of the project “Anti-tick Vac-
cines to Prevent Tick-borne Diseases in Europe. It is also
the name of the consortium that will push forward the
project. The consortium consists of seven European in-
stitutes funded by the European Commission through
the Seventh Framework Program for Research (FP7-
Health). The consortium is headed by Dr. Joppe Hovius,
Principal Investigator at the Academic Medical Center
in Amsterdam, and further consists of scientists from
the Institute of Parasitology at the Biology Centre of the
Academy of Sciences of the Czech Republic, the Insti-
tute for Parasitology and Tropical Veterinary Medicine
of the Freie Universität Berlin, Center for Cooperative
research in Biosciences from Spain, the medium-sized
enterprise GenXPro from Germany, the Institute of
Virology of the Slovak Academy of Sciences, and Dutch
National Institute for Public Health and Environment.
It brings together a unique combination of industrial,
research and public health institutes with ample research
experience on ticks, anti-tick immune responses, trans-
mission of tick-borne pathogens, anti-tick vaccines and
surveillance and control of vector-borne diseases. The
official launch meeting was held on December 1st, 2013
in Amsterdam (Figure 1).
The ANTIDotE project
ANTIDotE’s key objective is to identify antigens from I.
ricinus that could serve as candidates for an anti-tick
vaccine, which is able to protect against multiple European
tick-borne diseases (Figure 2). Using state of the art
proteomic and transcriptomic approaches we will iden-
tify and characterize novel tick salivary gland proteins,
which will be subsequently assessed as anti-tick vac-
cines to protect against Lyme borreliosis, TBE and
babesiosis in animal models. Importantly, this is notwhere ANTIDotE stops. We will also explore ways to
expedite and facilitate future utilization and implemen-
tation of anti-tick vaccines in public health systems [35].
Novel anti-tick vaccines could be used in humans and
finding a candidate that holds that potential and protects
against multiple human tick-borne diseases is ANTI-
DotE’s main ambition. However, as an alternative ap-
proach, anti-tick vaccines that interfere with tick feeding
and/or pathogen transmission could also be adapted
for use in domesticated animals or wildlife. This could
(locally) decrease tick or pathogen populations in the envir-
onment, which reduces the risk of contracting tick-borne
diseases for humans. The application of vaccines in domes-
ticated animals or wildlife to prevent human disease is a
challenge and there are only a few practically implemented
precedents [16]. Therefore, through a multidisciplinary and
integrated approach with several European public health
institutes, in collaboration with relevant stakeholders, such
as the European health organizations and end users, the
ANTIDotE consortium will examine if and how anti-tick
vaccines can be incorporated in health systems in Europe.
We will do so by organizing two workshops during the
five-year course of the project, at which the different
stakeholders (e.g. scientists, clinicians, public health
experts, and interested industrial partners) will be invited.
For more information we would like to refer to the website
www.antidote-fp7.org and interested institutes or individ-
uals are encouraged to contact the leader of the specific
work package, Dr. Hein Sprong, or the ANTIDotE coordin-
ator, Dr. Joppe WR Hovius.
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